Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110144 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
A Phase 2 study of Refractory Chronic Cough, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05110144 is a Phase 2 study of Refractory Chronic Cough that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 381-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05110144, a Phase 2 study of Refractory Chronic Cough, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)
Conditions Studied
Interventions
- DRUG Duloxetine 30 MG
- DRUG Amitriptyline 25 MG
- DRUG Amitriptyline 50 MG
- DRUG Duloxetine 60 MG
- DRUG Placebo 30 MG
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05110144
The ClinicalTrials.gov registry entry for NCT05110144 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Chronic Cough appearing as the primary indexed condition, and to 5 interventions - of which Duloxetine 30 MG is the first listed.
NCT05110144 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05110144 about?
NCT05110144 is a clinical study titled "Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough". This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)
What is the current status of trial NCT05110144?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-11-01. Estimated completion is 2026-12.
What conditions does trial NCT05110144 study?
This clinical trial studies the following conditions: Refractory Chronic Cough.
What interventions are being tested in trial NCT05110144?
The interventions under investigation include: Duloxetine 30 MG (DRUG), Amitriptyline 25 MG (DRUG), Amitriptyline 50 MG (DRUG), Duloxetine 60 MG (DRUG), Placebo 30 MG (DRUG).
Who is sponsoring clinical trial NCT05110144?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05110144 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Chronic Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Group Telehealth Behavioral Cough Suppression Therapy
RECRUITING · Early Phase 1
-
Cough Management Wellness App for Refractory or Unexplained Chronic Cough
RECRUITING · NA
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.